The NK-1 receptor is expressed in human melanoma and is involved in the antitumor action of the NK-1 receptor antagonist aprepitant on melanoma cell lines

Laboratory Investigation

Volumn 90, Issue 8, 2010, Pages 1259-1269

  Mũoz, Miguel ^a   Rosso, Marisa ^a   Robles Frias, María José ^a   Salinas Martín, Manuel Vicente ^a   Rosso, Rosario ^a   González Ortega, Ana ^a   Covẽas, Rafael ^b  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

antitumor; aprepitant; drug; melanoma; NK 1 receptor

Indexed keywords

APREPITANT; MESSENGER RNA; NEUROKININ 1 RECEPTOR; SUBSTANCE P; TETRAZOLIUM;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG TARGETING; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MALE; MELANOMA; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE; CELL PROLIFERATION; HUMANS; MELANOMA; MORPHOLINES; RECEPTORS, NEUROKININ-1; SKIN NEOPLASMS; SUBSTANCE P;

EID: 77955151651     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2010.92     Document Type: Article

References (44)

1. American Cancer Society. Cancer Facts and Figures 2007-2008. American Cancer Society: Atlanta, 2007.
2. Hökfelt T, Pernow B, Wahren J. Substance P: a pioneer amongst neuropeptides. J Intern Med 2001;249:27-40.
3. Harrison S, Geppetti P. Substance P. Int J Biochem Cell Biol 2001;33:555-576.
4. Muñoz M, Rosso M, Robles-Frías MJ, et al. Immunolocalization of the neurokinin-1 receptor: a new target in the treatment of the human primary retinoblastoma. In: Bospene EB (ed). Focus on Eye Neoplasma Research Advances. Nova Science Publishers: New York, 2008, pp 157-178.
5. Khare VK, Albino AP, Reed JA. The neuropeptide/mast cell secre-tagogue substance P is expressed in cutaneus melanocytic lesions. J Cutan Pathol 1998;25:2-10.
6. Muñoz M, Pérez A, Rosso M, et al. Antitumoural action of NK1 receptor antagonist L-733 060 on human melanoma cell lines. Melanoma Res 2004;14:183-188.
7. Esteban F, Muñoz M, González-Moles MA, et al. A role for substance P in cancer promotion and progression: a mechanism to counteract intracellular death signals following oncogene activation or DNA damage. Cancer Metast Rev 2006;25:137-145.
8. Luo W, Sharif TR, Sharif M. Substance P-induced mitogenesis in human astrocytoma cells correlates with activation of the mitogen-activated protein kinase signaling pathway. Cancer Res 1995;56:4983-4991.
9. Palma C, Nardelli F, Manzini S, et al. Substance P activates responses correlated with tumor growth in human glioma cells line bearing tachykinin NK1 receptors. Br J Cancer 1999;79:236-243.
10. Muñoz M, Rosso M, Pérez A, et al. The NK1 receptor is involved in the antitumoural action of L-733 060 and in the mitogenic action of substance P on neuroblastoma and glioma cell lines. Neuropeptides 2005;39:427-432.
11. Muñoz M, Rosso M, Pérez A, et al. Antitumoural action of the neurokinin-1-receptor antagonist L-733 060 and mitogenic action of substance P on human retinoblastoma cell lines. Invest Ophthalmol Vis Sci 2005;46:2567-2570.
12. Muñoz M, Rosso M, Coveñas R. The NK-1 receptor is involved in the antitumoural action of L-733 060 and in the mitogenic action of substance P on human pancreatic cancer cell lines. Lett Drug Des Discovery 2006;3:323-329.
13. Muñoz M, Rosso M, Soult JA, et al. Antitumoural action of neurokinin-1 receptor antagonists on human brain cancer cell lines. In: Yang AV (ed). Brain Cancer: Therapy and Surgical Intervention. Nova Science Publishers: New York, 2006, pp 45-75.
14. Muñoz M, Rosso M, Coveñas R. NK-1 receptor antagonists as new anti-tumoural agents: action on human neuroblastoma cell lines. In: Fernandes JA (ed). Focus on Neuroblastoma Research. Nova Science Publishers: New York, 2007, pp 31-56.
15. Muñoz M, Rosso M, Aguilar FJ, et al. NK-1 receptor antagonists induce apoptosis and counteract substance P-related mitogenesis in human laryngeal cancer cell line HEp-2. Investig New Drugs 2008;26:111-118.
16. Rosso M, Robles-Frías MJ, Coveñas R, et al. The NK-1 receptor is expressed in human primary gastric and colon adenocarcinomas and is involved in the antitumor action of L-733 060 and the mitogenic action of substance P on human gastrointestinal cancer cell lines. Tumor Biol 2008;29:245-254.
17. Ziche M, Morbidelli L, Pacini M, et al. Substance P stimulates neovascularization in vivo and proliferation of cultured endothelial cells. Microvasc Res 1990;40:264-278.
18. Lang K, Drell TL, Lindecke A, et al. Induction of a metastatogenic tumor cell type by neurotransmitters and its pharmacological inhibition by established drugs. Int J Cancer 2004;112:231-238.
19. Hennig IM, Laissue JA, Horisberger U, et al. Substance-P receptors in human primary neoplasms: tumoral and vascular localization. Int J Cancer 1995;61:786-792.
20. Singh D, Joshi DD, Hameed M, et al. Increased expression of preprotachykinin-I and neurokinin receptors in human breast cancer cells: implications for bone marrow metastasis. Proc Natl Acad Sci USA 2000;97:1388-1393.
21. Friess H, Zhu Z, Liard V, et al. Neurokinin-1 receptor expression and its potential effects on tumor growth in human pancreatic cancer. Lab Invest 2003;83:731-742.
22. Esteban F, González-Moles MA, Castro D, et al. Expression of substance P and neurokinin-1-receptor in laryngeal cancer: linking chronic inflammation to cancer promotion and progression. Histopathology 2008;4:258-260; in press DOI: 10.1111/j.1365-2559.2008.03193.x.
23. 1 tachykinin receptors in human tumors. J Histochem Cytochem 2006;54:1015-1020.
24. Muñoz M, Rosso M, Coveñas R, et al. Neurokinin-1 receptors located in human retinoblastoma cell lines: antitumor action of its antagonist, L-732 138. Invest Ophthalmol Vis Sci 2007;48:2775-2781.
25. Harrison T, Willians BJ, Swain CJ, et al. Piperidine-ether based hNK1 antagonists 1: determination of the relative and absolute stereochemical requirements. Bioorg Med Chem Lett 1994;4: 2545-2550.
26. Muñoz M, Pérez A, Coveñas R, et al. Antitumoural action of L-733 060 on neuroblastoma and glioma cell lines. Arch Ital Biol 2004;142: 105-112.
27. Kramer MS, Cutler N, Feighner J, et al. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 1998;81:1640-1645.
28. Varty GB, Cohen-Williams ME, Morgan CA, et al. The gerbil elevated plus-maze II: anxiolytic-like effects of selective neurokinin NK1 receptor antagonists. Neuropsychopharmacology 2002;27:371-379.
29. Tattersall FD, Rycroft W, Cumberbatch M, et al. The novel NK-1 receptor antagonist MK-0869 (L-754 030) and its water soluble phosphoryl prodrug, L-758 298, inhibit acute and delayed cisplatin-induced emesis in ferrets. Neuropharmacology 2000;39:652-663.
30. Muñoz M, Rosso M. The NK-1 receptor antagonist aprepitant as a broad spectrum antitumor drug. Invest New Drugs 2009;28:187-193; in press DOI: 10.1007/s10637-009-9218-8 A.
31. Bigioni M, Benzo A, Irrissuto C, et al. Role of NK-1 and NK-2 tachykinin receptor antagonism on the growth of human breast carcinoma cell line MDA-MB-231. Anticancer Drugs 2005;16:1083-1089.
32. Clark Jr WH, From L, Bernardino EA, et al. The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res 1969;29:705-727.
33. Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanomas. Ann Surg 1970;172:902-908.
34. kip1 determine Aplidin sensitivity. Mol Cancer Ther 2007;6:1310-1316.
35. 11] Substance P induces apoptosis in lung cancer cell lines in vitro. Biochem Bioph Res Com 1994;199:1313-1319.
36. Meshki J, Douglas SD, Lai JP, et al. Neurokinin 1 receptor mediates membrane blebbing in HEK293 cells through a Rho/Rho-associated coiled-coil kinase-dependent mechanism. J Biol Chem 2009;284: 9280-9289.
37. Fan TP, Hu DE, Guard S, et al. Stimulation of angiogenesis by substance P an interleukin-1 in the rat and its inhibition by NK1 or interleukin-1 receptor antagonists. Br J Pharmacol 1993;110:43-49.
38. Walsh DA, Hu DE, Mapp PI, et al. Innervation and neurokinin receptors during angiogenesis in the rat sponge granuloma. J Histochem Cytochem 1996;28:759-769.
39. Seegers HC, Hood VC, Kidd BL, et al. Enhancement of angiogenesis by endogenous substance P release and neurokinin-1 receptors during neurogenic inflammation. J Pharmacol Exp Ther 2003;306:8-12.
40. Guha S, Eibl G, Kisfalvi K, et al. Broad-spectrum G protein-coupled receptor antagonist, [D-Arg1,DTrp5,7,9,Leu11]SP: a dual inhibitor of growth and angiogenesis in pancreatic cancer. Cancer Res 2005;65:2738-2745.
41. Fackler OT, Grosse R. Cell motility through plasma membrane blebbing. J Cell Biol 2008;181:879-884.
42. Bang R, Sass G, Kiemer AK, et al. Neurokinin-1 receptor antagonists CP-96 345 and L-733 060 protect mice from cytokine-mediated liver injury. J Pharmacol Exp Ther 2003;305:31-39.
43. Rupniak NM, Carlson E, Boyce S, et al. Enantioselective inhibition of the formalin paw late phase by the NK1 receptor antagonist L-733 060 in gerbils. Pain 1996;67:189-195.
44. Yu J, Cadet JL, Angulo JA. Neurokinin-1 (NK-1) receptor antagonists abrogate methamphetamine-induced striatal dopaminergic neurotoxicity in the murine brain. J Neurochem 2002;83: 613-622.